Related by context. All words. (Click for frequent words.) 71 leiomyomas 70 papillary renal cell carcinoma 68 pulmonary metastases 68 gastric adenocarcinoma 68 LHRH receptor positive 67 prospective multicenter study 67 metastatic neuroendocrine tumors 67 urothelial 67 surgically resected 67 biliary tract cancer 67 clinicopathological 66 Sezary syndrome 66 nodal metastasis 66 fosbretabulin 66 esophageal carcinoma 66 urothelial carcinoma 66 prospectively evaluated 66 nonrandomized 66 metaplasia 66 osteoid osteoma 66 liposomal amphotericin B 66 intestinal metaplasia 66 primary hyperparathyroidism 66 mucinous 66 florbetaben 65 renal tumors 65 tumoral 65 etiologic factors 65 Histological 65 Estrogen Receptor 65 BRAF V#E 65 clinicopathologic 65 completely resected 65 cervical lymph nodes 65 nonmetastatic 65 riociguat 65 histologic subtype 65 prostate cancer CaP 65 Akt inhibitor 65 bronchogenic carcinoma 65 prostate carcinoma 65 Enzastaurin 65 CYT# potent vascular disrupting 65 polyarticular 65 calculi 65 receptor tyrosine kinase inhibitor 65 STRIDE PD 65 recurrent malignant glioma 65 multicenter Phase II 65 histologically confirmed 65 hyperplastic 65 Histopathologic 64 synovial 64 mycosis fungoides 64 Ultrasonographic 64 esophagogastric 64 HIV HCV coinfected 64 underwent resection 64 gastroduodenal 64 kidney urologic 64 recurrent ovarian 64 pheochromocytoma 64 mediastinal 64 HER2 expression 64 lymphadenopathy 64 immunohistochemical 64 esophageal gastric 64 basal cell carcinoma BCC 64 gastric carcinoma 64 mesenteric 64 lymphadenectomy 64 Papillary 64 Prospective Randomized 64 cervicitis 64 extracranial 64 transabdominal 64 gastric cardia 64 endobronchial 64 papillary thyroid carcinoma 64 colorectal adenocarcinoma 64 nephron sparing surgery 64 recurrent glioblastoma multiforme 64 transarterial 64 fallopian tube cancers 64 polycythemia vera PV 64 clinico pathological 64 randomized multicenter trial 64 fibrosing 64 multicenter prospective 64 peritoneal carcinomatosis 63 haematologic 63 multicenter randomized placebo controlled 63 immunohistochemical staining 63 aminotransferase 63 Synovial 63 ovarian carcinoma 63 intravesical therapy 63 osteoid 63 pulmonary metastasis 63 duplex ultrasonography 63 Cutaneous 63 obscure gastrointestinal bleeding 63 extranodal 63 epithelial tumors 63 Histopathological 63 Trandolapril 63 occlusive disease 63 prospective multicentre 63 Aplidin 63 multicentre study 63 bullous 63 inverse agonist 63 atherothrombosis 63 hamartomas 63 adrenalectomy 63 atherothrombotic disease 63 Histologically 63 pouchitis 63 SLNB 63 Ischemic 63 toenail onychomycosis 63 Histologic 63 ConclusionThis 63 Immunohistochemical staining 63 adenomatous 63 esophagogastric junction 63 histopathological 63 PAOD 63 immunocompetent 63 osteochondroma 63 urothelial cancer 63 Placebo controlled 63 thymectomy 63 pathogenetic 63 retroperitoneal 63 fibrotic disease 63 treat benign prostatic 63 relapsing remitting MS RRMS 63 rhITF 63 localized renal 63 breast carcinoma 63 demonstrated antitumor activity 63 colorectal carcinoma 63 antitumor effect 63 stage IIIB 63 supratentorial 63 superficial bladder cancer 63 colorectal liver metastases 63 neoplastic lesions 63 Fibroblast 63 aurora kinase 63 adrenocortical carcinoma 63 scintigraphic 63 keloid scarring 63 relapsed MM 63 IntroductionThe 63 urolithiasis 63 arteriography 63 Helicobacter pylori infection 63 concurrent chemoradiation 63 colorectal adenoma 63 tumorigenicity 63 metastatic malignant 63 Kahalalide F 63 bladder augmentation 63 HGPIN 63 etiologic 63 pseudotumor 62 pathologic diagnosis 62 myelofibrosis polycythemia vera 62 SSc 62 lymphoid malignancies 62 metastatic bladder 62 TRAIL R1 62 Endometrial 62 cerebral vasospasm 62 Adenomas 62 carcinoids 62 malignant neoplasms 62 recurrent metastatic 62 anterior uveitis 62 endoscopic ultrasonography 62 paragangliomas 62 dyskinetic 62 mediastinitis 62 multicenter Phase III 62 chronic thromboembolic pulmonary 62 refractory colorectal cancer 62 liver metastasis 62 lung carcinomas 62 histopathologic 62 pretransplant 62 supraclavicular 62 radiographic findings 62 neoplastic 62 multicenter trials 62 NSABP B 62 malignant ovarian 62 spinal metastases 62 #F FDG PET 62 sonographic appearance 62 antiphospholipid syndrome 62 ductal carcinomas 62 fibrosarcoma 62 HBeAg negative 62 ultrastructural 62 APTIMA HPV 62 neoadjuvant treatment 62 Deforolimus 62 haematological cancers 62 Neoplasms 62 demyelinating 62 pancreatic adenocarcinoma 62 noninfectious uveitis 62 FDG uptake 62 pT2 62 osteosarcomas 62 cytostatic 62 squamous cell carcinoma SCC 62 multicentre randomized 62 Renal Artery 62 hepatic metastases 62 NMIBC 62 transesophageal echocardiography 62 visceral metastases 62 pelvic malignancies 62 antiangiogenic agents 62 T1c 62 allogeneic HSCT 62 intraductal 62 5alpha reductase 62 multicentre 62 Oncogenic 62 NMDA antagonists 62 metastatic gastric 62 Nilotinib 62 Atherosclerotic 62 pharmacokinetic PK 62 pelvic lymphadenectomy 62 submucosal 62 peritumoral 62 intralesional 62 immunohistochemical analysis 62 chronic myocardial ischemia 62 gadolinium enhanced 62 ABCB1 62 Val HeFT 62 Systemic Lupus Erythematosus SLE 62 EGFR HER2 62 T2DM 62 hematological parameters 62 plexiform 62 SORT OUT III 62 diabetes mellitus DM 62 intrahepatic 62 lymphovascular invasion 62 synovial tissue 62 benign neoplasms 62 Patients Treated With 62 myocardial ischemia 62 haematological 62 sonographic findings 62 prostatic 62 lymphoid cells 62 prognostic marker 62 EORTC 62 transplantation HSCT 61 prostate cancer PCa 61 thrombo embolic 61 NIDDM 61 Aneurysm Repair 61 atherothrombotic 61 polyposis 61 artery stenosis 61 lymphomas leukemias 61 total thyroidectomy 61 adventitia 61 hepatocellular carcinoma HCC 61 neovascularisation 61 skeletal metastases 61 Biliary 61 chromosome #p# [002] 61 ductal adenocarcinoma 61 tumor necrosis 61 Lymph node 61 cardiac repolarization 61 benign prostatic hypertrophy BPH 61 selective agonists 61 mediastinum 61 potent antiproliferative 61 histologic findings 61 HeFH 61 idiopathic myelofibrosis 61 myelodysplastic myeloproliferative diseases 61 Randomized controlled 61 CC genotype 61 #p# [003] 61 preoperative diagnosis 61 urodynamic 61 Ultrasonography 61 Legg Calvé Perthes disease 61 mediated inhibition 61 thyroid carcinoma 61 polycythemia vera essential thrombocythemia 61 either acutely decompensated 61 activating mutation 61 cytologic 61 INS# [001] 61 hepatocellular carcinomas 61 hypertrophic scars 61 Coronary angiography 61 Squalamine 61 renal pelvis 61 neurological manifestations 61 Mycophenolate Mofetil 61 myometrium 61 genomic biomarker 61 histological subtype 61 extracapsular extension 61 murine model 61 prostatic tissue 61 essential thrombocythemia 61 APOL1 61 BPS IC 61 immuno modulatory 61 lung pancreatic 61 intraepithelial 61 antiphospholipid antibodies 61 malignant pancreatic 61 computed tomographic 61 cutaneous melanoma 61 stage IIIA 61 abacavir Ziagen 61 Multicenter 61 sonographically guided 61 ExTRACT TIMI 61 hepatic arterial 61 ß blockers 61 thorough QT 61 radiochemotherapy 61 COPERNICUS 61 hypervascular tumors 61 docetaxel Taxotere ® 61 Venous thromboembolism 61 prospective multicenter 61 prospectively stratified 61 epithelial ovarian 61 carotid plaques 61 Microalbuminuria 61 retrospective cohort 61 malignant lymphomas 61 Hypertrophy 61 MGd 61 metachronous 61 cMET 61 gene polymorphisms 61 Chronic Heart Failure 61 pituitary adenomas 61 VATS lobectomy 61 Prostatic 61 Overactive Bladder OAB 61 unresectable tumors 61 AKT inhibitor 61 TTR amyloidosis 61 T1a 61 histologically proven 61 tonsillar 61 acadesine 61 hydronephrosis 61 stage IIIb IV 61 metastatic lymph nodes 61 lymphoproliferative disorders 61 Systemic Sclerosis 61 thyroid nodules 61 pyelonephritis 61 HepDirect prodrug 61 pulmonary artery banding 61 metastatic RCC 61 GISTs 61 node metastasis 61 undergone radical prostatectomy 61 nonalcoholic steatohepatitis NASH 61 prospective multicenter randomized 61 β1 61 advanced metastatic renal 61 cervical lymph node 61 pain palliation 61 percutaneous vertebroplasty 61 atrophic gastritis 61 neuritic 61 transrectal ultrasound guided 61 cytological 61 osteogenic 61 paclitaxel eluting stents 61 mutated K ras 61 extrahepatic 61 vaso occlusive crisis 61 prospective nonrandomized 61 papillary RCC 61 complement inhibitor eculizumab 61 Polymorphisms 61 randomized Phase IIb 61 hyperlipidemic 61 transvaginal sonography 61 Lp PLA 2 61 prospective randomized controlled 61 tumor subtypes 61 BRAF V#E mutation 61 cytoreductive nephrectomy 61 myeloproliferative diseases 61 Prognostic factors 61 peripheral artery 61 XIENCE V demonstrated 61 patientswith 61 candidemia 61 Peripheral Arterial 61 fibroma 61 VEGF inhibitors 61 carcinoid tumors 61 pancreatic prostate 61 Angiographic 61 radicular 61 membranous nephropathy 61 Antitumor 61 Cloretazine R 61 sunitinib Sutent 61 cisplatin resistant 61 FDG PET imaging 61 Neovascular AMD 61 radiotherapy RT 61 cardio renal 61 obstructive coronary 61 radionuclide therapy 61 Asymptomatic 61 myxoid 61 sclerosing 61 haematological malignancies 61 splenic 61 erythropoietic 61 Hematologic 61 HIV seropositive 61 K ras mutations 61 valve implantation 61 orthotopic 61 Hypertrophic 61 syngeneic 61 Chronic Prostatitis 61 postoperative AF 60 atherosclerotic lesions 60 chemoradiotherapy 60 choroidal neovascularization 60 evaluating tivozanib 60 MEND CABG 60 NICE SUGAR 60 placebo controlled clinical 60 histologic examination 60 Hsp# Inhibitor 60 genomewide association study 60 Sjögren syndrome 60 invasive carcinoma 60 C. trachomatis 60 Lymphocytic 60 adrenocortical 60 axilla 60 anti angiogenic agents 60 vitreous floaters 60 facial clefts 60 mesangial 60 GH deficiency 60 Hemangiomas 60 Clinical Outcome 60 endothelial activation 60 Metastases 60 perianal 60 prospective randomized multicenter 60 parenchymal 60 prognostic significance 60 Complicated Skin 60 operable breast cancer 60 choroidal 60 HepaSphere 60 node metastases 60 CHEK2 60 CP CPPS 60 chemoresistant 60 Cardiotoxicity 60 hepatocellular 60 RhuDex R 60 prostate carcinomas 60 Hodgkin lymphoma HL 60 Sudhir Agrawal D.Phil 60 multicenter randomized controlled 60 metastatic pancreatic 60 somatostatin analog 60 eccrine 60 femoral neck fractures 60 randomized multicenter 60 vinca alkaloid 60 retrospectively analyzed 60 lenalidomide dexamethasone 60 adipogenic 60 HDL Selective Delipidation 60 biliary stones 60 Malignancies 60 multicentre randomized controlled 60 leiomyoma 60 digital subtraction angiography 60 noninflammatory 60 Intracranial 60 ultrasonographic examination 60 Mitomycin C 60 hamartoma 60 pulmonary hypertension PH 60 polypoid 60 Aplidin R 60 clade B 60 Subgroup analyzes 60 GORE TAG Device 60 BEXXAR Therapeutic Regimen 60 Hematological 60 Tumor Response 60 Soft Tissue Sarcoma 60 BRCA deficient 60 thetreatment 60 endocervical 60 oropharyngeal 60 colon carcinoma 60 aetiology 60 diagnostic biomarker 60 pleomorphic 60 nonischemic 60 Chronic lymphocytic leukemia 60 CINQUIL 60 calcaneal fractures 60 cutaneous squamous cell carcinoma 60 Diabetic nephropathy 60 thymoma 60 hematopoietic cancers 60 liver resection 60 colonoscopic 60 pleural effusions 60 Atypical Hemolytic Uremic Syndrome 60 transurethral resection 60 number NCT# ClinicalTrials.gov 60 paroxysmal AF 60 IL# PE#QQR 60 chest radiograph 60 basilar 60 Glioma 60 malignant pleural mesothelioma 60 Mutational 60 factor Xa inhibitor 60 BERKELEY CA UroToday.com 60 ultrasonographic 60 hypertrophic scarring 60 familial amyloidotic polyneuropathy FAP 60 BRIM2 60 needle aspiration 60 dyslipidaemia 60 retrospective cohort study 60 renal cysts 60 J Am Coll 60 antiproliferative effects 60 Radical prostatectomy 60 gefitinib Iressa 60 Candida infection 60 symptomatic paroxysmal AF 60 transplantation HCT 60 Edge STudy 60 essential thrombocythemia ET 60 endoluminal 60 huN# DM1 60 axillary lymph node 60 randomized multicentre 60 renal cell carcinomas 60 miconazole Lauriad ® 60 multicenter phase 60 Randomized Study 60 multivessel disease 60 lesional 60 Safinamide 60 BrachySil TM 60 hepatoma 60 MELAS 60 oncologic outcomes 60 schwannomas 60 immunostaining 60 prognostic biomarker 60 Bacteremia 60 Hepatic 60 Coronary Artery Bypass Graft 60 transesophageal 60 Immunotherapeutic 60 tiuxetan 60 longitudinal cohort study 60 percutaneous transluminal coronary angioplasty 60 nodular 60 CTEPH 60 medically inoperable 60 Hepatocellular Carcinoma HCC 60 mononuclear 60 RhuDex TM 60 N. Engl 60 granulomatous 60 variceal bleeding 60 microvessel 60 thyroglobulin 60 papillary carcinoma 60 HCV SPRINT 60 ADPKD 60 malignant ascites 60 sonographic evaluation 60 HDACi 60 HNSCC 60 Idiopathic 60 descending thoracic 60 multicentre prospective 60 LUMINATE 60 T1DM 60 Erythropoietic 60 Metastatic 60 motor neuron degeneration 60 reflux esophagitis 60 antiangiogenic therapy 60 arthrography 60 clinicopathological features 60 Surgical resection 60 IV NSCLC 60 histone deacetylase inhibitor 60 fluorescein angiography 60 neoadjuvant 60 ventricular myocardium 60 TransVax ™ 60 thalidomide Thalomid 60 invasive candidiasis 60 cutaneous T 60 trabectedin 60 prucalopride 60 prognostically 60 risk reducing salpingo 60 extramedullary 60 chemoprevention trials 60 ALA PDT 60 Aflibercept 60 intravenous cyclophosphamide 60 ABSSSI 60 Squamous Cell Carcinoma 60 antibody MAb 60 Acute Decompensated Heart Failure 60 Resection 60 gene rearrangements 60 dysplastic 60 lacunar 60 hypereosinophilic syndrome 60 AA Amyloidosis 60 prognostic variables 60 oral deforolimus 60 TG MV 60 HLA DRB1 * 60 RTOG 60 circulating endothelial cells 60 Diamondback #deg 60 metastatic colorectal 60 germline mutation 60 sorafenib Nexavar 60 p# biomarker 60 intravesical 60 substudy 60 arthropathy 60 acute myeloid 60 BR.# 60 β blockers 60 adrenocortical cancer 60 Chemokine Receptor 60 myeloproliferative 60 cytoreduction 60 thrombophilia 60 sinonasal 60 nasopharyngeal carcinoma 60 novel VDA molecule 60 Denufosol 60 Randomised 60 functional gastrointestinal disorders 60 taxane resistant 60 lipomas 60 micafungin 60 ELACYT 60 intracavitary 60 superficial femoral 60 Leukemias 60 Antiviral Therapy 60 controlled multicenter 60 Zollinger Ellison Syndrome 60 anti angiogenic therapy 60 CLL SLL 60 tumor excision 60 percutaneous biopsy 60 Thrombolysis 60 PDGF receptor 60 blinded randomized placebo controlled 60 INCB# [003] 60 Myocardial Infarction Study 59 Immunohistochemical analysis 59 Lymphoid 59 Histopathology 59 hormone receptor negative 59 galiximab 59 endothelin receptor 59 intradermal injections 59 submandibular gland 59 airway hyperresponsiveness 59 Zemplar Capsules 59 susceptibility loci 59 spontaneous regression 59 myogenic cell 59 plasma pharmacokinetics 59 tumor histology 59 Advanced Renal Cell 59 multimodality therapy 59 gonococcal 59 dose escalation clinical 59 transitional cell carcinoma 59 cholelithiasis 59 CML CP 59 preoperative evaluation 59 sCD# 59 Pharmacodynamic 59 atherosclerotic disease 59 colorectal gastric 59 Etiology 59 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 59 Accelerated Partial Breast Irradiation 59 CLORETAZINE TM VNP#M 59 subgroup analyzes 59 Clinical Relevance 59 Hepatocellular Carcinoma 59 psoriatic arthritis PsA 59 stratifying patients 59 efficacy evaluable 59 KRAS oncogene 59 YONDELIS R 59 headache nasopharyngitis 59 metastatic GIST 59 malignant neoplasm 59 Angiotensin Converting Enzyme 59 VP# [004] 59 Pivotal Trial 59 lymph node enlargement 59 Fas ligand 59 stenoses 59 ANCA associated 59 proctitis 59 interstitial fibrosis 59 renal biopsy 59 peripheral arterial 59 prostate TURP 59 repair TEVAR 59 Catheter Associated 59 pharmacodynamic PD 59 pT3 59 antrum 59 DDP# 59 Glycosylation 59 locoregional recurrence 59 ALB # 59 metastatic adenocarcinoma 59 ENMD # 59 Embolization 59 thyroid carcinomas 59 hyperalgesia 59 myocardial revascularization 59 Chronic Pelvic Pain 59 Refractory Angina 59 unstable angina UA 59 thymosin beta 4 59 subconjunctival injection 59 Mucosal 59 pancreatic colon 59 lymphocytic 59 micrometastasis 59 pseudoaneurysms 59 Multiple Myeloma MM 59 bronchoalveolar lavage 59 cutaneous lupus 59 Trichophyton rubrum 59 antiangiogenic agent 59 corneal epithelial 59 REALITY Trial 59 MGUS 59 intracerebral 59 motesanib diphosphate 59 authors hypothesized 59 hepatobiliary 59 osteoblastic 59 metastatic malignant melanoma 59 Carotid 59 Cardiac Allograft Rejection 59 CALGB 59 PCa 59 stem cell transplantations 59 trial evaluating PRX# 59 insertional 59 EDEMA3 trial 59 multicenter randomized clinical 59 relapsed ALL 59 ischemic mitral regurgitation 59 hyperinsulinemic euglycemic clamp 59 fallopian tube carcinoma 59 situ LCIS 59 proliferative retinopathy 59 chronic periodontitis 59 steroid refractory 59 CCR9 59 extra articular 59 Meta analyzes 59 Lubiprostone 59 micrometastases 59 giant cell arteritis 59 transthyretin amyloidosis 59 neoadjuvant therapy 59 genetic polymorphisms 59 femoral neck fracture 59 plasmacytoid 59 trials RCTs 59 Metastatic Melanoma 59 subarachnoid hemorrhage SAH 59 treatment naive genotype 59 interobserver 59 hepatic cirrhosis 59 surgically resectable 59 F FDG PET 59 histologic diagnosis 59 extrapulmonary 59 blinded randomized 59 cinacalcet 59 Phase #b/#a clinical 59 Metastatic breast cancer 59 pharmacokinetic PK study 59 CEUS 59 small molecule tyrosine 59 selective modulator 59 TMPRSS2 ERG fusion 59 kinase inhibition 59 pancreatic carcinoma 59 flutamide 59 chromosomal rearrangement 59 metaanalysis 59 Esophageal 59 antiplatelet medications 59 heparin induced thrombocytopenia 59 resectable 59 patients undergoing CABG 59 Occlusive Disease 59 intratumoral 59 juvenile idiopathic arthritis 59 Coronary artery 59 melanocytic 59 Percutaneous Transluminal Coronary Angioplasty 59 clinically evaluable 59 PsA 59 Alkaline Phosphatase 59 unstable angina pectoris 59 malignant prostate 59 carcinoid tumor 59 LV dysfunction 59 AtherOx 59 pericardial effusion 59 tumor lysis syndrome 59 hypercoagulable 59 observational cohort study 59 IBS C 59 IPAH 59 Helicobacter pylori eradication 59 cystoid macular edema 59 resected tumors 59 benign uterine 59 hyperhomocysteinemia 59 untreated metastatic melanoma 59 arterial revascularization 59 urethral stricture 59 situ CIS 59 ASTEROID 59 FDG-PET/CT 59 Acute Coronary Syndromes ACS 59 hyperechoic 59 Temsirolimus 59 hepatorenal syndrome 59 MAGE A3 ASCI 59 Sipuleucel T 59 Feasibility Trial 59 Phase III Clinical Trial 59 urography 59 histologic 59 pharmacokinetic parameters 59 phase IIIb 59 Onychomycosis 59 cytologically confirmed 59 Raf MEK ERK 59 mTOR mammalian target 59 Radiation Therapy Oncology 59 CARE HF 59 Randomized Double blind 59 pyrimidine 59 Phase #b/#a 59 conformal radiotherapy 59 acute leukemias 59 follicular thyroid cancer 59 CagA 59 histologies 59 excisional biopsy 59 hypercholesterolemic patients 59 independent prognostic marker 59 angioplasty stenting 59 lymph node metastasis 59 sonographic 59 ADMIRE HF 59 gene polymorphism 59 atypical hemolytic uremic syndrome 59 castrate resistant prostate cancer 59 debulking surgery 59 morphologic 59 monoclonal anti 59 locoregional 59 vesicoureteral reflux 59 Left Ventricular Dysfunction 59 Langerhans cell histiocytosis 59 Carotid Revascularization Endarterectomy vs. 59 Phase IIb III 59 surgical debulking 59 intravesical infusion therapy 59 virally induced 59 inactivating mutations 59 prospective observational 59 lymph node dissection 59 Hematopoietic 59 Tyrosine Kinase Inhibitor 59 histopathologic examination 59 wedge resection 59 PKC inhibitors 59 clonal expansion 59 macules 59 para aortic 59 headache abdominal pain 59 nodal metastases 59 Cutaneous T 59 HMGA1 59 Factor VIIa 59 RezularTM 59 neoplasm 59 torsade de pointes 59 Phase III multicenter 59 benign prostatic hyperplasia enlarged 59 genes differentially expressed 59 Gleevec resistant 59 prospectively enrolled 59 Polymorphism 59 Autoantibodies 59 MADIT II 59 carcinomatosis 59 conjunctival 59 herpetic 59 perfusion imaging 59 IL 1ß 59 non resectable 59 lobular carcinomas 59 prospective longitudinal 59 CIMZIA TM certolizumab pegol 59 NSABP 59 epididymal 59 aerosolized KL4 surfactant 59 posaconazole 59 embolizations 59 TMC# C# 59 Cardiac catheterization 59 angiographically 59 asplenia 59 hepatic lesions 59 hyperuricaemia 59 thrombi 59 ostial 59 hemodynamically significant 59 randomized controlled multicenter 59 advanced adenoma 59 strontium ranelate 59 Upregulation 59 TACI Ig 59 intraepithelial neoplasia 59 peri implant 59 antitumour activity 59 icatibant 59 pathologic examination 59 MVA MUC1 IL2 59 hilar 59 nasal polyposis 59 ano genital warts 59 hypointense 59 radical cystectomy 59 recurrent DVT 59 Fluorouracil